Testicular cancer - new approaches in surgery and systemic treatment

**Location:** Room Paris, North Hall (Level 1)

**Chairs:**
- M. Jewett, Toronto (CA)
- D.L. Nicol, London (GB)
- N. Nicolai, Milan (IT)

**Aims and objectives of this session**
This session will update the audience with new indications and outcome results from surgical approaches together with new systemic treatment options for patients with advanced germ cell cancer. In addition, quality of care issues will be discussed based on large registries.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (•) are 3 minutes in length, followed by 3 minutes for discussion.

---

1084

**Non-guideline concordant treatment of testicular cancer**

**By:** Paffenholz P., Pfister D., Heidenreich A.

**Institutes:** University Hospital Cologne, Dept. of Urology, Cologne, Germany

---

1085

**Testicular cancer in patients with learning disabilities in England from 2001-2015: A national cohort study**

**By:** Afshar M. ², Jackson-Spence F. ¹, De Santis M. ³, Tanner J-R. ¹, Evison F. ⁵, James N. ³, Selby P. ⁶, Patel P. ⁷

**Institutes:** University of Birmingham, Medical School, Birmingham, United Kingdom, ²St George’s University Hospitals NHS Foundation Trust, Dept. of Urological Oncology, London, United Kingdom, ³University of Warwick, Cancer Research Unit, Coventry, United Kingdom, ⁴University Hospitals Birmingham NHS Foundation Trust, Dept. of Oncology, Birmingham, United Kingdom, ⁵University Hospitals Birmingham NHS Foundation Trust, Dept. of Informatics, Birmingham, United Kingdom, ⁶University of Leeds, Leeds Institute of Cancer & Pathology, Leeds, United Kingdom, ⁷University of Birmingham, School of Cancer Sciences, Birmingham, United Kingdom

---

1086

**Reliability of frozen section examination in a large cohort of testicular masses: What did we learn?**

**By:** Vartolomei M.D. ¹, Matei D.V. ², Renne G. ³, Tringali V.M. ², Ferro M. ², Bianchi R. ², Russo A. ², Cozzi G. ², De Cobelli O. ⁴

**Institutes:** University of Medicine and Pharmacy, Targu Mures, Romania and European Institute of Oncology, Dept. of Cell and Molecular Biology and Dept. of Urology, Milan, Italy, ²European Institute of Oncology, Dept. of Urology, Milan, Italy, ³European Institute of Oncology, Dept. of Pathology, Milan, Italy, ⁴European Institute of Oncology and University of Milan, Dept. of Urology, Milan, Italy

---

1087

**Diagnostic value of frozen section examination (FSE) during inguinal exploration in patients with inconclusive testicular lesions**

**By:** Fankhauser C. ¹, Beyer J. ², Roth L. ³, Sulser T. ¹, Bode K-P. ², Moch H. ³, Hermanns T. ¹

**Institutes:** University Hospital Zurich, University of Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital Zurich, University of Zurich, Dept. of Oncology, Zurich, Switzerland, ³University Hospital Zurich, University of Zurich, Dept. of Pathology and Molecular Pathology, Zurich, Switzerland

---

1088

**Safety of testicular prosthesis insertion at the time of radical orchiectomy for testis cancer in patients undergoing adjuvant therapies**

**By:** Musi G. ¹, Cozzi G. ¹, Bianchi R. ¹, Mistretta F.A. ¹, Tringali V.M.L. ¹, Jereczeck B.A. ², Nolé F. ³, De...
Poster Session 82

1089

Laparoscopic retroperitoneal lymph-node dissection (L-RPLND) is not only a staging procedure in stage I non-seminomatous germ-cell testicular tumors (NSGCTT): Mature data from a referral centre

By: Nicolai N.¹, Tarabelloni N.², Catanzaro M.¹, Gasperoni F.², Stagni S.¹, Torelli T.¹, Tesone A.¹, Kungulli A.¹, Necchi A.³, Giannatempo P.³, Raggi D.³, Colecchia M.⁴, Salvioni R.³, Piva L.³, Pizzocaro G.⁵, Biasoni D.¹

Institutes: Fondazione Ircs Istituto Nazionale Tumori, Dept. of Urology, Milan, Italy, Mox-Politecnico Di Milano, Dept. of Mathematics, Milan, Italy, Fondazione Ircs Istituto Nazionale Tumori, Dept. of Medical Oncology, Milan, Italy, Fondazione Ircs Istituto Nazionale Tumori, Dept. of Pathology, Milan, Italy, Fondazione Ircs Istituto Nazionale Tumori, Emeritus, Milan, Italy

1090

Primary retroperitoneal lymph node dissection (RPLND) in Stage II A/B seminoma patients without adjuvant treatment: A phase II trial (PRIMETEST)

By: Lusch A., Gerbaulet L., Winter C., Albers P.

Institutes: Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

1091

Surgical resection of residual tumours after adjuvant chemotherapy of germ cell (GC) tumour

By: Gonzalez F.¹, Bossavy J-P.¹, Otal P.², Quintyn–Rant M-L.², Roumigué M.⁴, Chevreau C.⁵, Malavaud B.⁴


1092

Complications and adjunctive surgical procedures in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) to define a tertia referral center

By: Lusch A., Gerbaulet L., Winter C., Albers P.

Institutes: Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

1093

Bone metastases in germ cell tumours: Surgical management and outcomes

By: Nini A.¹, Konieczny M.², Winter C.³, Lusch A.³, Krauspe R.³, Albers P.³

Institutes: IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Orthopedic Surgery, Düsseldorf, Germany, University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Urology, Düsseldorf, Germany

1094

Retinal toxicity after cisplatin-based chemotherapy in patients with testicular cancer

By: Gild P.¹, Vetterlein M.¹, Dieckmann K.P.², Matthis C.³, Wagner W.³, Ludwig T.¹, Meyer C.¹, Soave A.¹, Dulz S.⁴, Asselborn N.⁴, Oechsle K.⁵, Bokemeyer C.⁵, Becker A.¹, Fisch M.¹, Hartmann M.¹, Chun F.¹, Kluth L.A.¹

Institutes: University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, Albertinen Hospital, Dept. of Urology, Hamburg, Germany, Bundeswehr Medical Center Hamburg, Dept. of Urology, Hamburg, Germany, University Medical Center Hamburg-Eppendorf, Dept. of Ophthalmology, Hamburg, Germany, University Medical Center Hamburg-Eppendorf, Dept. of Medical Oncology, Hamburg, Germany

1095

The features and management of late relapse of non-seminomatous germ cell tumours

By: Jay A., Aldiwani M., Wijayarathna S., Huddart R., Mayer E., Nicol D.

Institutes: Royal Marsden Hospital, Dept. of Urology, Chelsea, United Kingdom

1096

Incidence of secondary malignancies (SM) in patients (pts) with germ cell tumors (GCT) who received high-dose chemotherapy (HDCT): A retrospective study from the European Society for Blood and Marrow Transplantation (EBMT) database
**Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase 2 Pazotest trial**

**By:** Necchi A.\(^1\), Lo Vullo S.\(^2\), Giannatempo P.\(^3\), Raggi D.\(^1\), Calareso G.\(^4\), Togliardi E.\(^4\), Crippa F.\(^5\), Pennati M.\(^6\), Zaffaroni N.\(^6\), Perrone F.\(^7\), Colecchia M.\(^7\), Nicolai N.\(^8\), Mariani L.\(^2\), Salvioni R.\(^8\)

**Institutes:** Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, \(^2\)Fondazione IRCCS Policlinico San Matteo, Dept. of Medical Oncology, Pavia, Italy, \(^3\)EBMT Study Offices, Paris, France, \(^4\)Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, \(^5\)Hospital of Ravenna, Dept. of Hematology, Ravenna, Italy

---

**Final comments**

N. Nicolai, Milan (IT)